Ocufilcon D

Summary

Ocufilcon D (CHEMBL2108456) is a phase-3 clinical-stage small molecule.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Small molecule
• Clinical trials: 5

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL2108456
Name	Ocufilcon D
Type	Small molecule
Max phase	3

Also known as: Ocufilcon d, OCUFILCON D

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

0 indications (0 at ChEMBL trial phase 4).

Clinical trials

Total trials: 5.

Phase distribution

Phase	Trials
Not specified	5

Top trials by phase / activity

NCT	Phase	Status	Title
NCT01163760	Not specified	COMPLETED	Clinical Evaluation of Two Daily Disposable Contact Lenses
NCT01464255	Not specified	COMPLETED	Comparative Study of Two Marketed 1-day Soft Contact Lenses
NCT02131402	Not specified	COMPLETED	Clinical Performance of Hydrogel vs. Silicone Hydrogel Contact Lenses
NCT02406495	Not specified	COMPLETED	Clinical Performance of Habitual Wearers of Bioclear 1-day Lenses When Refitted With Biomedics 1-day Extra for 1 Week
NCT02727816	Not specified	COMPLETED	Non-dispensing Fitting Study Comparing the Clinical Performance Hydrogel Sphere Design Contact Lenses.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).